Reduced Risk of Barrett’s Esophagus in Statin Users: Case–Control Study and Meta-Analysis

Digestive Diseases and Sciences

Volumn 61, Issue 1, 2016, Pages 238-246

  Beales, Ian L P ^a,b   Dearman, Leanne ^a   Vardi, Inna ^a   Loke, Yoon ^b  

^a NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

Aspirin; Barrett s esophagus; Esophageal cancer; Statins

Indexed keywords

ACETYLSALICYLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

AGED; BARRETT ESOPHAGUS; CASE CONTROL STUDY; CHI SQUARE DISTRIBUTION; ENGLAND; GASTROSCOPY; HUMAN; INCIDENCE; MALE; META ANALYSIS; MIDDLE AGED; ODDS RATIO; PROTECTION; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; TIME FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BARRETT ESOPHAGUS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; ENGLAND; GASTROSCOPY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PROTECTIVE FACTORS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 84952990006     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-015-3869-4     Document Type: Article

References (44)

1. Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst. 2008;100:1184–1187.
2. Wu X, Chen VW, Andrews PA, Ruiz B, Correa P. Incidence of esophageal and gastric cancers among Hispanics, non-Hispanic whites and non-Hispanic blacks in the United States: subsite and histology differences. Cancer Causes Control. 2007;18:585–593.
3. Alexandre L, Long E, Beales IL. Pathophysiological mechanisms linking obesity and esophageal adenocarcinoma. World J Gastrointest Pathophysiol. 2014;5:534–549.
4. Long E, Beales IL. The role of obesity in oesophageal cancer development. Therap Adv Gastroenterol. 2014;7:247–268.
5. Sikkema M, de Jonge PJ, Steyerberg EW, Kuipers EJ. Risk of esophageal adenocarcinoma and mortality in patients with Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2010;8:235–244.
6. Yousef F, Cardwell C, Cantwell MM, Galway K, Johnston BT, Murray L. The incidence of esophageal cancer and high-grade dysplasia in Barrett’s esophagus: a systematic review and meta-analysis. Am J Epidemiol. 2008;168:237–249.
7. Desai TK, Krishnan K, Samala N, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett’s oesophagus: a meta-analysis. Gut. 2012;61:970–976.
8. Shaheen NJ, Overholt BF, Sampliner RE, et al. Durability of radiofrequency ablation in Barrett’s esophagus with dysplasia. Gastroenterology. 2011;141:460–468.
9. Dubecz A, Gall I, Solymosi N, et al. Temporal trends in long-term survival and cure rates in esophageal cancer: a SEER database analysis. J Thorac Oncol. 2012;7:443–447.
10. Ogunwobi OO, Beales IL. Statins inhibit proliferation and induce apoptosis in barrett’s esophageal adenocarcinoma cells. Am J Gastroenterol. 2008;103:825–837.
11. Fang D, Das KM, Cao W, et al. Barrett’s esophagus: progression to adenocarcinoma and markers. Ann N Y Acad Sci. 2011;1232:210–229.
12. Beales IL, Ogunwobi OO. Microsomal prostaglandin E synthase-1 inhibition blocks proliferation and enhances apoptosis in oesophageal adenocarcinoma cells without affecting endothelial prostacyclin production. Int J Cancer. 2010;126:2247–2255.
13. Kastelein F, Spaander MC, Biermann K, Steyerberg EW, Kuipers EJ, Bruno MJ. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett’s esophagus. Gastroenterology. 2011;141:2000–2008.
14. Beales IL, Vardi I, Dearman L. Regular statin and aspirin use in patients with Barrett’s oesophagus is associated with a reduced incidence of oesophageal adenocarcinoma. Eur J Gastroenterol Hepatol. 2012;24:917–923.
15. Beales I, Vardi I, Dearman L, Broughton T. Statin use is associated with a reduction in the incidence of esophageal adenoncarcinoma: a case–control study. Dis Esophagus. 2013;26:838–846.
16. Beales IL, Hensley A, Loke Y. Reduced esophageal cancer incidence in statin users, particularly with cyclo-oxygenase inhibition. World J Gastrointest Pharmacol Ther. 2013;4:69–79.
17. Singh S, Singh AG, Singh PP, Murad MH, Iyer PG. Statins are associated with reduced risk of esophageal cancer, particularly in patients with barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013;11:620–629.
18. Alexandre L, Clark AB, Bhutta HY, Holt S, Lewis MP, Hart AR. Statin use is associated with reduced risk of histologic subtypes of esophageal cancer: a nested case–control analysis. Gastroenterology. 2014;146:661–668.
19. Broughton T, Sington J, Beales IL. Statin use is associated with a reduced incidence of colorectal adenomatous polyps. Int J Colorectal Dis. 2013;28:469–476.
20. Alexandre L, Broughton T, Loke Y, Beales IL. Meta-analysis: risk of esophageal adenocarcinoma with medications which relax the lower esophageal sphincter. Dis Esophagus. 2012;25:535–544.
21. Nguyen T, Khalaf N, Ramsey D, El-Serag HB. Statin use is associated with a decreased risk of Barrett’s esophagus. Gastroenterology. 2014;147:314–323.
22. Omer ZB, Ananthakrishnan AN, Nattinger KJ, et al. Aspirin protects against Barrett’s esophagus in a multivariate logistic regression analysis. Clin Gastroenterol Hepatol. 2012;10:722–727.
23. Broughton T, Sington J, Beales IL. Statin use is associated with a reduced incidence of colorectal cancer: a colonoscopy-controlled case–control study. BMC Gastroenterol. 2012;12:36.
24. Balasubramanian G, Gupta N, Giacchino M, et al. Cigarette smoking is a modifiable risk factor for Barrett’s oesophagus. United European Gastroenterol J. 2013;1:430–437.
25. Jacobson BC, Chan AT, Giovannucci EL, Fuchs CS. Body mass index and Barrett’s oesophagus in women. Gut. 2009;58:1460–1466.
26. Rubenstein JH, Morgenstern H, Chey WD, et al. Protective role of gluteofemoral obesity in erosive oesophagitis and Barrett’s oesophagus. Gut. 2014;63:230–235.
27. Nguyen DM, Richardson P, El-Serag HB. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett’s esophagus. Gastroenterology. 2010;138:2260–2266.
28. Masclee GM, Coloma PM, Spaander MC, Kuipers EJ, Sturkenboom MC. NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett’s oesophagus: a population-based case–control study. BMJ Open. 2015;5:e006640.
29. Yokota K, Miyazaki T, Hirano M, Akiyama Y, Mimura T. Simvastatin inhibits production of interleukin 6 (IL-6) and IL-8 and cell proliferation induced by tumor necrosis factor-alpha in fibroblast-like synoviocytes from patients with rheumatoid arthritis. J Rheumatol. 2006;33:463–471.
30. Lazzerini PE, Lorenzini S, Selvi E, et al. Simvastatin inhibits cytokine production and nuclear factor-kB activation in interleukin 1beta-stimulated synoviocytes from rheumatoid arthritis patients. Clin Exp Rheumatol. 2007;25:696–700.
31. Lin D, Kramer JR, Ramsey D, et al. Oral bisphosphonates and the risk of Barrett’s esophagus: case–control analysis of US veterans. Am J Gastroenterol. 2013;108:1576–1583.
32. Goldberg A, Gerkin RD, Young M. Medical Prevention of Barrett’s esophagus: effects of statins, aspirin, non-aspirin NSAIDs, calcium, and multivitamins. Dig Dis Sci. 2015;60:2058–2062.
33. Thrift AP, Pandeya N, Smith KJ, Green AC, Webb PM, Whiteman DC. The use of nonsteroidal anti-inflammatory drugs and the risk of Barrett’s oesophagus. Aliment Pharmacol Ther. 2011;34:1235–1244.
34. Cheong E, Igali L, Harvey I, et al. Cyclo-oxygenase-2 expression in Barrett’s oesophageal carcinogenesis: an immunohistochemical study. Aliment Pharmacol Ther. 2003;17:379–386.
35. Macfarlane TV, Lefevre K, Watson MC. Aspirin and non-steroidal anti-inflammatory drug use and the risk of upper aerodigestive tract cancer. Br J Cancer. 2014;111:1852–1859.
36. Zhang S, Zhang XQ, Ding XW, et al. Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with Barrett’s esophagus: a meta-analysis. Br J Cancer. 2014;110:2378–2388.
37. Sivarasan N, Smith G. Role of aspirin in chemoprevention of esophageal adenocarcinoma: a meta-analysis. J Dig Dis. 2013;14:222–230.
38. Dovizio M, Bruno A, Tacconelli S, Patrignani P. Mode of action of aspirin as a chemopreventive agent. Recent Results Cancer Res. 2013;191:39–65.
39. Fang Y, Chen X, Bajpai M, et al. Cellular origins and molecular mechanisms of Barrett’s esophagus and esophageal adenocarcinoma. Ann N Y Acad Sci. 2013;1300:187–199.
40. Ogunwobi OO, Beales IL. Leptin stimulates the proliferation of human oesophageal adenocarcinoma cells via HB-EGF and Tgfalpha mediated transactivation of the epidermal growth factor receptor. Br J Biomed Sci. 2008;65:121–127.
41. Ogunwobi OO, Beales IL. Globular adiponectin, acting via adiponectin receptor-1, inhibits leptin-stimulated oesophageal adenocarcinoma cell proliferation. Mol Cell Endocrinol. 2008;285:43–50.
42. Beales IL, Garcia-Morales C, Ogunwobi OO, Mutungi G. Adiponectin inhibits leptin-induced oncogenic signalling in oesophageal cancer cells by activation of PTP1B. Mol Cell Endocrinol. 2013;382:150–158.
43. Ogunwobi O, Mutungi G, Beales IL. Leptin stimulates proliferation and inhibits apoptosis in Barrett’s esophageal adenocarcinoma cells by cyclooxygenase-2-dependent, prostaglandin-E2-mediated transactivation of the epidermal growth factor receptor and c-Jun NH2-terminal kinase activation. Endocrinology. 2006;147:4505–4516.
44. Beales IL, Ogunwobi OO, Cameron E, El-Amin K, Mutungi G, Wilkinson M. Activation of Akt is increased in the dysplasia-carcinoma sequence in Barrett’s oesophagus and contributes to increased proliferation and inhibition of apoptosis: a functional and immunohistochemical study. BMC Cancer. 2007;7:97.